Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mesoblast Limited (MESO : NSDQ)
 
 • Company Description   
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Number of Employees: 73

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.86 Daily Weekly Monthly
20 Day Moving Average: 211,282 shares
Shares Outstanding: 127.78 (millions)
Market Capitalization: $1,387.67 (millions)
Beta: 2.39
52 Week High: $22.00
52 Week Low: $5.78
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.24% -9.14%
12 Week -1.99% -14.11%
Year To Date -45.15% -48.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
LEVEL 38 55 COLLINS STREET
-
MELBOURNE VICTORIA,C3 3000
AUS
ph: 61-3-9639-6036
fax: 61-3-9639-6030
investors@mesoblast.com http://www.mesoblast.com
 
 • General Corporate Information   
Officers
Silviu Itescu - Chief Executive Officer
Jane Bell - Chair of Board
Dagmar Rosa-Bjorkeson - Chief Operating Officer
Andrew Chaponnel - Chief Financial Officer
Michael Spooner - Director

Peer Information
Mesoblast Limited (CORR.)
Mesoblast Limited (RSPI)
Mesoblast Limited (CGXP)
Mesoblast Limited (BGEN)
Mesoblast Limited (GTBP)
Mesoblast Limited (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 590717401
SIC: 2836
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: 08/27/25
Share - Related Items
Shares Outstanding: 127.78
Most Recent Split Date: 1.00 (0.50:1)
Beta: 2.39
Market Capitalization: $1,387.67 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.43 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/27/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.98
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 0.96
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 0.63
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 3.64
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.22
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 18.03
 

Powered by Zacks Investment Research ©